G007-LK: Selective Tankyrase 1/2 Inhibitor for Wnt/β-Catenin Research

Executive Summary: G007-LK is a potent, selective small-molecule inhibitor targeting tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), with nanomolar IC50 values (46 nM and 25 nM, respectively) for auto-poly(ADP-ribosyl)ation inhibition [product]. In Wnt3a-induced HEK 293 cells, G007-LK inhibits Wnt signaling reporter ST-Luc with an IC50 of 0.05 μM, demonstrating cellular efficacy [Jia et al. 2017]. The compound induces β-catenin degradation and AXIN1/2 stabilization in APC-mutant colorectal cancer models, reducing tumor growth in vivo [Jia et al. 2017]. G007-LK also modulates the Hippo pathway by upregulating AMOTL1/2 and downregulating YAP, indicating its utility for advanced cancer signal transduction studies [Jia et al. 2017]. APExBIO supplies G007-LK (B5830), supporting reproducible research workflows in cancer biology [product].

Biological Rationale

Tankyrases (TNKS1/2) are members of the poly(ADP-ribosyl)ating polymerase (PARP) family. They regulate assembly and disassembly of protein complexes, Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression [Jia et al. 2017]. Elevated tankyrase expression is observed in various cancers, including colorectal and hepatocellular carcinoma (HCC) [Jia et al. 2017]. Aberrant Wnt/β-catenin activity, often due to APC mutations, drives tumorigenesis in colorectal cancer and is implicated in HCC progression [Amadacycline article]. Tankyrase inhibition suppresses Wnt/β-catenin signaling by stabilizing AXIN1/2, scaffolding proteins critical for β-catenin destruction [HBCAG article]. G007-LK enables targeted dissection of these pathways, supporting research in signal transduction and tumor biology.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds selectively to the catalytic PARP domain of tankyrase 1 and 2, inhibiting auto-poly(ADP-ribosyl)ation with IC50 values of 46 nM (TNKS1) and 25 nM (TNKS2) [product]. This inhibition prevents tankyrase-mediated degradation of AXIN1/2, resulting in increased AXIN levels and enhanced assembly of β-catenin destruction complexes. Consequently, cytosolic and nuclear β-catenin levels decrease, reducing transcription of Wnt/β-catenin target genes [Jia et al. 2017]. In APC-mutant colorectal cancer cells (e.g., SW480), G007-LK induces formation of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. In HCC models, tankyrase inhibition upregulates AMOTL1 and AMOTL2, negative regulators of YAP, thereby downregulating YAP/TEAD transcriptional activity and modulating the Hippo pathway [Jia et al. 2017].

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC50 values of 46 nM and 25 nM, respectively (APExBIO product documentation: https://www.apexbt.com/g007-lk.html).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter (ST-Luc) with an IC50 of 0.05 μM (Jia et al. 2017, https://doi.org/10.1371/journal.pone.0184068).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces formation of β-catenin degradasomes and reduces cytosolic/nuclear β-catenin levels (Jia et al. 2017, https://doi.org/10.1371/journal.pone.0184068).
• In vivo, G007-LK inhibits tumor growth in COLO-320DM xenograft mouse models and reduces TNKS1/2 and β-catenin protein levels while stabilizing AXIN1/2 (Jia et al. 2017, https://doi.org/10.1371/journal.pone.0184068).
• In hepatocellular carcinoma cell lines, G007-LK reduces YAP protein levels, inhibits YAP/TEAD reporter activity, and upregulates AMOTL1/2 proteins (Jia et al. 2017, https://doi.org/10.1371/journal.pone.0184068).
• G007-LK demonstrates synergy with MEK and AKT inhibitors in suppressing HCC cell proliferation (Jia et al. 2017, https://doi.org/10.1371/journal.pone.0184068).

This article extends the mechanistic landscape presented in "Strategic Horizons in Wnt/β-Catenin and Hippo Pathway Mod..." by providing a granular, citation-rich analysis of G007-LK’s cellular benchmarks and workflow parameters. It also clarifies the utility of G007-LK as described in "G007-LK: Tankyrase 1/2 Inhibitor for Precision Wnt Signal..." by detailing quantifiable inhibitor potencies and in vivo antitumor data.

Applications, Limits & Misconceptions

G007-LK is primarily used in research to:

• Dissect tankyrase function in Wnt/β-catenin and Hippo pathway signaling.
• Model APC mutation-driven colorectal cancer and hepatocellular carcinoma in vitro and in vivo.
• Study mechanisms of β-catenin degradation and AXIN1/2 stabilization.
• Screen for synergistic effects with kinase inhibitors in cancer cell lines.

However, G007-LK is not a therapeutic drug and should not be used in humans or for diagnostic purposes. Its activity is context-dependent; efficacy can vary across cell types and experimental conditions. G007-LK’s solubility profile (≥26.5 mg/mL in DMSO; insoluble in water/ethanol) may limit certain in vivo or high-throughput applications. Misconceptions often arise regarding its selectivity; while highly selective for tankyrase 1/2, off-target effects at high concentrations cannot be excluded.

Common Pitfalls or Misconceptions

• G007-LK is not active in water or ethanol; dissolution requires DMSO and may need warming or sonication.
• It is not a direct β-catenin inhibitor; its effect is mediated via tankyrase inhibition and AXIN stabilization.
• G007-LK is not a drug candidate; it is for research use only and lacks regulatory approval for human use.
• Synergistic effects with other pathway inhibitors (e.g., MEK, AKT) are context- and cell-type-dependent.
• Long-term storage of G007-LK solutions is not recommended; use freshly prepared solutions for reproducibility.

Workflow Integration & Parameters

G007-LK (B5830) from APExBIO is supplied as a solid and should be stored at -20°C. For optimal solubility, dissolve the compound in DMSO at ≥26.5 mg/mL, optionally warming to 37°C or using an ultrasonic bath. Working concentrations in cell-based assays typically range from 25 nM to 1 μM, with IC50 values of 46 nM (TNKS1), 25 nM (TNKS2), and 0.05 μM (Wnt ST-Luc in HEK 293 cells) [product]. For in vivo studies, formulation protocols must address DMSO content, vehicle compatibility, and dosing schedule. Avoid prolonged storage of solutions to ensure potency. For detailed protocols and mechanistic rationale, see the companion article here, which this article updates with new benchmark data.

Conclusion & Outlook

G007-LK is an essential tool for dissecting tankyrase-dependent Wnt/β-catenin and Hippo signaling in cancer models, particularly APC-mutant colorectal cancer and hepatocellular carcinoma. Its nanomolar potency, selectivity, and reproducibility support robust mechanistic research. Future work may focus on combinatorial strategies and translational models, leveraging G007-LK to unravel resistance mechanisms and identify new therapeutic targets. For detailed product specifications and ordering, visit the G007-LK tankyrase 1/2 inhibitor page at APExBIO. For strategic context, see the analysis in "Advancing Cancer Biology: Mechanistic and Strategic Insig...", which this article extends by providing granular biochemical and cellular benchmarks.